ABSTRACT:
Bicalutamide is an anti-cancer drug used for metastatic prostate cancer treatment. A new stability indicating RP-HPLC method was developed and validated for the determination of Bicalutamide in tablets. Shimadzu HPLC Model no. iSeries 2050C 3D with Lab solutions Software with PDA detector and Inertsil C8 column (150 x 4.6 mm., 5mm) were used for the present study. Phosphate buffer (pH adjusted to 2.90 using ortho phosphoric acid) was used as mobile phase A and a mixture of Acetonitrile: Methanol: Water (80: 10: 10, v/v) was used as mobile phase B with flow rate 1.3 mL/min were the optimised chromatographic conditions (Detection wavelength 270 nm). The method was linear over the concentration range 0.1-120mg/ml with linear regression equation, y = 20351x + 980.75 (R² = 0.9999). The LOQ and LOD were found to be 0.0919mg/ml and 0.0301 respectively. Stress degradation studies were performed and the method was validated as per ICH guidelines.
Cite this article:
Hema, Naresh Panigrahi. A New Stability Indicating RP-HPLC Method for the Estimation of Bicalutamide. Research Journal Pharmacy and Technology. 2025;18(8):3817-3. doi: 10.52711/0974-360X.2025.00549
Cite(Electronic):
Hema, Naresh Panigrahi. A New Stability Indicating RP-HPLC Method for the Estimation of Bicalutamide. Research Journal Pharmacy and Technology. 2025;18(8):3817-3. doi: 10.52711/0974-360X.2025.00549 Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2025-18-8-52
REFERENCES:
1. Furr BJ, Tucker H. The preclinical development of Bicalutamide: Pharmacodynamics and mechanism of action. Urology. 1996; 47(1A Suppl): 13-25; discussion 29-32.
2. Palleshwar Rao G, Rao JVLNS, Rama Prasad AL and Srinivasu P. Development and validation of a new stability indicating HPLC method for quantification of process related and degradation impurities of Bicalutamide in tablet dosage forms. Int J Pharm 2012; 2(1): 218-223.
3. Nageswara Rao R, Narasa Raju A and R. Narsimha Isolation and characterization of process related impurities and degradation products of Bicalutamide and development of RP-HPLC method for impurity profile study. Journal of Pharmaceutical and Biomedical Analysis 2008; 46(3): 505-519.
4. A Lakshmana Rao, G. Taraka Ramesh and J.V.L.N.S. Rao. Development and validation of RP-HPLC method for the estimation of Bicalutamide in pure and pharmaceutical dosage forms. Rasayan Journal of Chemistry 2009; 2(2): 512-515.
5. Nanduri VV, Adapa VS, Kura RR. Development and validation of stability-indicating HPLC and UPLC methods for the determination of Bicalutamide. Journal of Chromatogr Science 2012; 50(4): 316-323.
6. Saravanan G, Rao BM, Ravikumar M et al. A stability-indicating LC assay method for Bicalutamide. Chromatographia 2007; 66: 219-222.
7. Kim B, Shim JH, Lee SH, Yu KS, Yoon SH and and Cho JY. Liquid chromatography tandem mass spectrometry determination of Bicalutamide in human plasma and application to a bioequivalence study. Bioanalysis and Biomedicine, 2011; 3: 98-102.
8. Pradhan VR, Pudage A, Patankar S, Sawant S. and Rathnam MV. Validation of chiral liquid chromatography-tandem mass spectrometric method for the estimation of Bicalutamide enantiomers in human plasma: Application to a bioequivalence study. International Journal of Bioassays. 2013; 2: 1210-1222.
9. Pradhan VR and Rathnam MV. Liquid chromatography-tandem mass spectrometric method for the estimation of R-Bicalutamide in human plasma. International Journal of Biopharma Research. 2014; 3: 186-192.
10. Ramarao NT, Vidyadhara S, Sasidhar RLC, Deepti B and Yadav RS. Development and validation of LC-MS/MS method for the quantification of chiral separated R-Bicalutamide in human plasma. American Journal of Analytical Chemistry. 2013; 4: 63-76.
11. Sharma K, Pawar GV, Giri S, Rajagopal S and Mullangi R. Development and validation of a highly sensitive LC-MS/MS-ESI method for the determination of Bicalutamide in mouse plasma: Application to a pharmacokinetic study. Biomedical Chromatography. 2012; 26: 1589-1595.
12. Suresh PS, Vijay Kumar S, Kumar A and Mullangi R. Development of an LC-MS/MS method for determination of bicalutamide on dried blood spots: Application to pharmacokinetic study in mice. Biomedical Chromatography. 2015; 29: 254-260.
13. Ajjala D, Mudigonda K, Kandikere V and Niorgi R. Therapeutic drug monitoring of Bicalutamide in human plasma using HPLC. AAPS Annual Meeting and Exposition. 2007; 11-15 November, poster no. W4066.
14. ICH Q2 (R1) Validation of analytical procedures: Text and methodology (2005).
15. ICH Q1A (R2) Stability testing of new drug substances and products (2003).